ClinicalTrials.gg
TerminatedNCT04156100Updated Mar 3, 2022

A Study in Subjects With Advanced Solid Tumors

A Phase 1 interventional study of AGEN1223 and AGEN1223 and balstilimab in Advanced Solid Tumor, sponsored by Agenus Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Agenus Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Strategic business decision.

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors.

Read the detailed description

This study is an open-label, Phase 1 study to evaluate the safety, tolerability, PK, and pharmacodynamic profiles of AGEN1223 as a single-agent and in combination with balstilimab, as well as to assess the maximum tolerated dose and determine the RP2D of AGEN1223 as a single-agent and in combination with balstilimab in subjects with advanced solid tumors. This Phase 1 study will be conducted in an accelerated titration (for the first 2 single agent AGEN1223 dosing cohorts) and standard 3+3 dose escalation format. Study drug treatment will be administered on Day 1 of each 3-week cycle for up to 2 years or until any progressive disease (PD) or unacceptable toxicity is reported. The timing of the administration of doses may be adjusted for management of adverse events (AEs). The safe starting dose of AGEN1223 single-agent will be at the estimated minimally anticipated biological effect level.

The treatment phase is divided into 3-week cycles with associated evaluations and procedures that must be performed at specific time points. Tumor assessments will be conducted every 6 weeks (±7 days) from first dose until treatment discontinuation or disease progression. In subjects that discontinue treatment for reasons other than PD, imaging will continue until PD or initiation of a new therapy. If the subject discontinues treatment because of PD, imaging may be performed if clinically beneficial or if deemed necessary by the investigator until the initiation of new antineoplastic therapy. This must be approved by the Sponsor.

A Safety Monitoring Committee (SMC) will be established to assess safety and determine dose escalation.

02

Conditions studied

  • Advanced Solid Tumor

Browse trials for

Keywords

  • Cancer, Solid Tumor, PD-L1
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 19 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Agenus Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily agree to participate by giving signed, dated, and written prior to any study specific procedures (participation in genetic testing is optional).
  2. Greater than or equal to 18 years of age
  3. or cytologically confirmed diagnosis of an advanced solid tumor for which no standard therapy is available or standard therapy has failed.
  4. on baseline imaging based on 1.1.
  5. of at least 3 months and an performance status of 0 or 1 (Appendix A).
  6. Adequate organ function as indicated by the following laboratory values:

    • Adequate hematological function, defined as ≥1.5 × 109/L, count ≥100 × 109/L, and ≥8 g/dL without recent transfusion (defined as a transfusion that has occurred within 2 weeks of the hemoglobin measurement).
    • Adequate hepatic function based by a total level ≤1.5 × the institutional (IULN), level ≤2.5 × IULN, ALT level ≤2.5 × IULN.
    • Adequate renal function defined as creatinine ≤1.5 × IULN or measured or calculated >40 mL/min per institutional standard. Assessment methods should be recorded.
    • Adequate coagulation defined by or prothrombin time ≤1.5 × IULN and activated partial thromboplastin time ≤1.5 × IULN (unless the subject is receiving anticoagulant therapy).
  7. No history of prior or concomitant that requires other active treatment.
  8. Subjects must provide a sufficient and adequate FFPE tumor tissue sample (fresh ) collected within 28 days before the first dose from a site not previously irradiated and to agree to a mandatory on-treatment biopsy if clinically feasible.
  9. Female subjects of must have a negative serum pregnancy test at screening (within 72 hours of first dose of study medication). Subjects with tumors producing human chorionic gonadotropin and gestational trophoblastic tumor do not need a serum pregnancy test, and absence of pregnancy should be documented by the Principal Investigator (PI) based on clinical and radiological assessments as needed. Non-childbearing potential is defined as:

    • ≥45 years of age and has not had menses for greater than 1 year,
    • Amenorrheic for ≥2 years without a hysterectomy and oophorectomy and a follicle-stimulating hormone value in the range upon prestudy (screening) evaluation,
    • Status is post-hysterectomy, oophorectomy, or tubal ligation.
  10. Female subjects of child-bearing potential must be willing to use highly effective measures starting with the screening visit through 90 days after the last dose of study treatment.

    Note: Abstinence is acceptable if this is the established and preferred contraception for the subject.

  11. Male subjects with a female partner(s) of child-bearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 90 days after the last dose of study treatment is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

    Note: Abstinence is acceptable if this is the established and preferred contraception method for the subject.

  12. Willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigation device within 3 weeks of the first dose of current study drug.
  2. Any relevant bispecific antibody, and/or /PDL1 agents. For selected indication cohorts, prior treatment may be permitted after discussion with the Sponsor. Prior therapy with PD-1/PDL1 inhibitor may be allowed in agreement with the Sponsor.
  3. Received prior systemic cytotoxic chemotherapy, biological therapy, radiotherapy, or major surgery within 3 weeks prior to first dose of study drug; a 1-week is permitted for palliative radiation to non-central nervous system (CNS) disease with Sponsor approval.
  4. Persisting toxicity with Grade >1 severity related to prior therapy based on Version 5.0.

    Note: Sensory neuropathy and alopecia of Grade ≤2 are acceptable.

  5. Expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent, radiation therapy, and/or surgical resection).
  6. Known severe reactions (NCI-CTCAE Grade ≥3) to fully human monoclonal antibodies, or severe reaction to immuno-oncology agents, such as colitis or pneumonitis, requiring treatment with , or has a history of interstitial lung disease (ILD), any history of anaphylaxis, or uncontrolled asthma.
  7. Receiving systemic corticosteroid therapy 1 week prior to the first dose of study drug or receiving any other form of systemic medication.

    Note: Corticosteroid use as a premedication for IV contrast allergies/reactions is allowed. Subjects who are receiving daily corticosteroid replacement therapy are an exception to this rule. Daily prednisone at doses of up to 7.5 mg or equivalent hydrocortisone doses are examples of permitted replacement therapy. Use of inhaled or topical corticosteroids is permitted.

  8. CNS tumor, , and/or carcinomatous meningitis identified either on the baseline brain imaging obtained during the screening period or identified prior to consent.

    Note: Subjects with history of that have been treated may participate provided they show evidence of stable supra-tentorial lesions at screening (defined as 2 brain images, both of which are obtained after treatment to the brain metastases; these imaging scans should both be obtained ≥4 weeks apart). In addition, any neurologic symptoms that developed either as a result of the brain metastases or their treatment must have returned to baseline or resolved. Any steroids administered as part of this therapy must be completed ≥3 days prior to the first dose of study medication.

  9. Active or history of disease that has required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).

    Note: Subjects with diabetes type 1, vitiligo, psoriasis, and hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

  10. Allogeneic tissue/solid organ transplant, except those not requiring immuno-suppressive treatment.
  11. Active infection requiring treatment.
  12. History of (HIV) type 1 or 2 antibodies.
  13. Known active whose virus load is greater than 500 IU/mL.
  14. (i.e., active) cardiovascular disease: cerebral vascular accident/stroke or myocardial infarction within 6 months of enrollment, unstable angina, congestive heart failure ( class ≥II), or serious uncontrolled cardiac arrhythmia requiring medication.
  15. History or current evidence of any condition, therapy, active infections, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  16. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
  17. Legally incapacitated or has limited legal capacity.
  18. Pregnant or breastfeeding.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    AGEN1223

    AGEN1223 is a bispecific antibody.

    Drug: AGEN1223

  • Experimental
    AGEN1223 and balstilimab

    AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody

    Drug: AGEN1223 and balstilimab

Interventions

  • DrugAGEN1223

    AGEN1223 is a bispecific antibody.

  • DrugAGEN1223 and balstilimab

    Drug page: Balstilimab

    AGEN1223 is a bispecific antibody and balstilimab an anti-PD-1 Monoclonal Antibody.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    In subjects in dose escalation

    Time frame: First 28 days of treatment

  2. Frequency, severity, and duration of treatment-emergent AEs (TEAEs)

    For all dose groups according to NCI-CTCAE Version 5.0

    Time frame: Screening through 90 days after last dose

Secondary outcomes

  1. Maximum observed concentration at steady state (Cmax-ss)

    PK profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  2. Minimum observed concentration at steady state (Cmin-ss)

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  3. Area under the plasma/serum concentration-time curve within time span t1 to t2 at steady-state (AUC(t1-t2)-ss)

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  4. Area under the plasma/serum concentration-time curve from time zero to time t (AUC(0-t))

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  5. Area under the plasma/serum concentration-time curve from time zero to infinity (AUC(0-∞))

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  6. Time to maximum observed concentration (tmax)

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  7. terminal disposition rate constant (λz)

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  8. Terminal elimination half-life (t1/2)

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  9. Systemic clearance (CL)

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  10. Volume of distribution (Vd).

    PK Profile of AGEN1223 and balstilimab

    Time frame: From first dose through 2 year of treatment

  11. Immunogenicity

    Incidence of anti-AGEN1223 antibodies and anti-Balstilimab antibodies

    Time frame: From first dose through 2 year of treatment

  12. Overall Response Rate

    Per RECIST 1.1 based on Investigator assessment

    Time frame: Screening up to 2 years of treatment

  13. Duration of Response

    Per RECIST 1.1 based on Investigator assessment

    Time frame: Screening up to 2 years of treatment

  14. Disease Control Rate

    Including complete and partial responders and stable disease (SD) for at least 12 weeks, per RECIST 1.1 based on Investigator assessment.

    Time frame: Screening up to 2 years of treatment

  15. Progression-free Survival median and/or rate

    As defined in the Statistical Analysis Plan

    Time frame: Screening up to 2 years of treatment

Other outcomes

  1. PK parameter correlation to pharmacodynamic assessments

    Immune cell subpopulations in blood

    Time frame: Screening up to 1 year of treatment

  2. Characterization of genetic polymorphism of FcyR

    In subjects treated with AGEN1223 as single-agent and in combination with balstilimab

    Time frame: Screening up to 2 years of treatment

  3. Biomarkers of pharmacologic activity

    Correlation with tumor responses to AGEN1223 and balstilimab treatment

    Time frame: Screening up to 1 year of treatment

  4. Biomarkers in tumor tissue and blood

    Correlation with tumor responses to AGEN1223 and balstilimab treatment

    Time frame: Screening up to 1 year of treatment

  5. Median and/or rate of Overall Survival

    As defined in the Statistical Analysis Plan

    Time frame: Up to 12 months after last dose

07

Study locations

4 sites
  • HonorHealth Research Institute
    Scottsdale, Arizona 85258, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of Miami/Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Abramson Cancer Center at the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2019 to primary completion in Apr 2021, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Nov 7, 2019
StartActual
Dec 10, 2019
Primary completionActual
Apr 8, 2021
CompletionActual
Sep 29, 2021
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04156100
Lead sponsor
Agenus Inc.
Responsible party
Sponsor
First posted
Nov 7, 2019
Start date
Dec 10, 2019
Primary completion
Apr 8, 2021
Completion
Sep 29, 2021
Last update
Mar 3, 2022

Study contacts

Medical Director
study director · Agenus Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balstilimab

Start the discussion